Orphenadrine Versus Baclofen in Treatment of Muscle Cramps in Cirrhotic Patients
NCT ID: NCT04509336
Last Updated: 2022-04-29
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
NA
5 participants
INTERVENTIONAL
2020-08-20
2021-09-20
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Study of Orphenadrine' in the Treatment of Muscle Cramps in Patients With Cirrhosis
NCT02423395
Baclofen in the Treatment of Muscle Cramps in Patients With Cirrhosis
NCT02221570
Methocarbamol in Treatment of Muscle Cramps in Cirrhotic Patients
NCT02642874
Effect of Branched-chain Amino Acids (BCAA) to Muscle Cramps in Patients With Cirrhosis
NCT05724485
MNK-6105 for Patients With Cirrhosis and High Ammonia Levels Affecting Brain Function
NCT04128462
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
orphenadrine group
orphenadrine
Orphenadrine
100 mg twice daily
Baclofen group
Baclofen
Baclofen
initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Orphenadrine
100 mg twice daily
Baclofen
initial dose of 10 mg tablet once daily, dose will be gradually increased according to the patients responses
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Cirrhotic patients complaining of frequent muscle cramps (\>3 per week) for at least a month
Exclusion Criteria
2. Renal impairment
3. Peripheral vascular disease
4. Peripheral neuropathy
5. Glaucoma
6. Prostatic enlargement
7. Pregnancy and lactation
8. Patients taking calcium channel blockers, and conjugated estrogens
9. Patients taking vitamin E, taurine, carnitine, narcotic pain medications, muscle relaxants, nonsteroidal anti-inflammatory drugs, or antispastic agents during and for 2 weeks following the study
10. Patients with alcoholic cirrhosis
18 Years
70 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Mansoura University
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Noha Mansour
Lecturer of clinical pharmacy, pharmacy practice department
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Assem Elfert
Role: STUDY_CHAIR
Tanta University
Sherif Abd-Elsalam
Role: PRINCIPAL_INVESTIGATOR
Tanta University
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Tanta University Hospitals
Tanta, , Egypt
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
2020-87
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.